Clinical Trial ChallengesBased on adverse events, tissue and plasma findings, tolerability, and antitumor activity, EVANGELINE will proceed as a randomized trial comparing endoxifen 40mg/day with ovarian function suppression vs. exemestane with ovarian function suppression.
Market CompetitionThe oral SERD space in second-line and beyond patients has become increasingly competitive, though to date, Phase 3 trials have only indicated a benefit in ESR1 mutant patients.
Treatment DurabilityZ-endoxifen's tolerability as a selective estrogen receptor modulator positions it well in the metastatic breast cancer setting, where current treatments often provide limited durability and considerable side effects.